Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

September 26, 2021

Study Completion Date

September 26, 2021

Conditions
Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

OZURDEX

Implant 700 μg

Trial Locations (9)

100730

Peking Union Medical College Hospital /ID# 233616, Beijing

Beijing Tongren Hospital, CMU /ID# 233608, Beijing

116011

The First Affiliated Hospital of Dalian Medical University /ID# 233688, Dalian

200031

The Eye and ENT Hospital Affiliated of Fudan Univesity /ID# 233666, Shanghai

200080

Shanghai General Hospital /ID# 233579, Shanghai

250012

Qilu Hospital of Shandong University /ID# 233605, Jinan

300020

Tianjin Eye Hospital /ID# 233581, Tianjin

410008

The First Xiangya Hospital of Central South University /ID# 233627, Changsha Hunan

515041

Joint Shantou International Eye Center of Shantou University and The Chinese Uni /ID# 233580, Shantou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY